Dr. Elizabeth ("Betsy") Haanes advises biotechnology companies on best practices for the worldwide protection of their intellectual property. In all aspects of her practice, she focuses on creating innovative, long-term legal strategies that integrate seamlessly into her clients' technological and business objectives.
As an accomplished scientist with a Ph.D. in microbiology, Dr. Haanes speaks the same language as today's biotechnology innovators. For more than 15 years, she has helped these innovators protect their technological assets even in the face of recent court opinions that have posed significant challenges to patent holders.
Dr. Haanes counsels her clients on the creation and management of high-value patent portfolios, freedom-to-operate and patentability issues, validity and infringement issues, and due diligence investigations in connection with acquisitions and investments. She represents a diverse body of entities in technology areas such as vaccines, infectious diseases, medical diagnostics, biomarkers, personalized medicine, therapeutic antibodies, therapeutic nucleic acids, genomics, proteomics, and gene therapy.
Dr. Haanes has lectured and written extensively on the problem of patent eligibility for innovations in the areas of biomarkers, medical diagnostics, and personalized medicine. She co-authored an article in the journal Nature Biotechnology discussing the impact of the U.S. Supreme Court's 2012 decision in Mayo v. Prometheus. She also co-wrote an amicus brief in Merck v. Integra, a landmark U.S. Supreme Court case focusing on the patent infringement safe harbor for drug development research.
As a scientist, Dr. Haanes previously performed infectious disease and vaccine research, both in academia and industry. She published widely in the areas of microbial pathogenesis, molecular virology, and vaccines and is an inventor on numerous patents and published applications relating to recombinant vaccines.